Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology

被引：5

作者：

Mishra, Hemant K. ^{[1
]}

Kalyuzhny, Alex ^{[2
]}

机构：

[1] Cellinfinitybio, San Francisco, CA 94107 USA

[2] Biotechne 2, Minneapolis, MN 55413 USA

来源：

CELLS | 2024年 / 13卷 / 18期

关键词：

induced pluripotent stem cells (iPSCs); chimeric antigen receptor (CAR); immunotherapy; differentiation; IPSCS;

D O I：

10.3390/cells13181516

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Recent advances in cellular therapies have paved the way for innovative treatments of various cancers and autoimmune disorders. Induced pluripotent stem cells (iPSCs) represent a remarkable breakthrough, offering the potential to generate patient-specific cell types for personalized as well as allogeneic therapies. This review explores the application of iPSC-derived chimeric antigen receptor (CAR) T cells, a cutting-edge approach in allogeneic cancer immunotherapies. CAR T cells are genetically engineered immune cells designed to target specific tumor antigens, and their integration with iPSC technology holds immense promise for enhancing the efficacy, safety, and scalability of cellular therapies. This review begins by elucidating the principles behind iPSC generation and differentiation into T cells, highlighting the advantage of iPSCs in providing a uniform, inexhaustible source of CAR T cells. Additionally, we discuss the genetic modification of iPSC-derived T cells to express various CARs, emphasizing the precision and flexibility this affords in designing customized therapies for a diverse range of malignancies. Notably, iPSC-derived CAR T cells demonstrate a superior proliferative capacity, persistence, and anti-tumor activity compared to their conventionally derived counterparts, offering a potential solution to challenges associated with conventional CAR T cell therapies. In conclusion, iPSC-derived CAR T cells represent a groundbreaking advancement in cellular therapies, demonstrating unparalleled potential in revolutionizing the landscape of immunotherapies. As this technology continues to evolve, it holds the promise of providing safer, more effective, and widely accessible treatment options for patients battling cancer and other immune-related disorders. This review aims to shed light on the transformative potential of iPSC-derived CAR T cells and inspire further research and development in this dynamic field.

引用

页数：12

共 68 条

[1] Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy [J].

Abou-el-Enein, Mohamed ;

Elsallab, Magdi ;

Feldman, Steven A. ;

Fesnak, Andrew D. ;

Heslop, Helen E. ;

Marks, Peter ;

Till, Brian G. ;

Bauer, Gerhard ;

Savoldo, Barbara .

BLOOD CANCER DISCOVERY, 2021, 2 (05) :408-422

[2]

[Anonymous], 2024, Considerations for the development of chimeric antigen receptor (CAR) T cell products

[3] UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial [J].

Benjamin, Reuben ;

Jain, Nitin ;

Maus, Marcela V. ;

Boissel, Nicolas ;

Graham, Charlotte ;

Jozwik, Agnieszka ;

Yallop, Deborah ;

Konopleva, Marina ;

Frigault, Matthew J. ;

Teshima, Takanori ;

Kato, Koji ;

Boucaud, Floriane ;

Balandraud, Svetlana ;

Gianella-Borradori, Athos ;

Binlich, Florence ;

Marchiq, Ibtissam ;

Dupouy, Sandra ;

Almena-Carrasco, Maria ;

Pannaux, Matthieu ;

Fouliard, Sylvain ;

Brissot, Eolia ;

Mohty, Mohamad .

LANCET HAEMATOLOGY, 2022, 9 (11) :E833-E843

[4] Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies [J].

Benjamin, Reuben ;

Graham, Charlotte ;

Yallop, Deborah ;

Jozwik, Agnieszka ;

Mirci-Danicar, Oana C. ;

Lucchini, Giovanna ;

Pinner, Danielle ;

Jain, Nitin ;

Kantarjian, Hagop ;

Boissel, Nicolas ;

Maus, Marcela V. ;

Frigault, Matthew J. ;

Baruchel, Andre ;

Mohty, Mohamad ;

Gianella-Borradori, Athos ;

Binlich, Florence ;

Balandraud, Svetlana ;

Vitry, Fabien ;

Thomas, Elisabeth ;

Philippe, Anne ;

Fouliard, Sylvain ;

Dupouy, Sandra ;

Marchiq, Ibtissam ;

Almena-Carrasco, Maria ;

Ferry, Nicolas ;

Arnould, Sylvain ;

Konto, Cyril ;

Veys, Paul ;

Qasim, Waseem .

LANCET, 2020, 396 (10266) :1885-1894

[5] Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells [J].

Cael, Blandine ;

Galaine, Jeanne ;

Bardey, Isabelle ;

Marton, Chrystel ;

Fredon, Maxime ;

Biichle, Sabeha ;

Poussard, Margaux ;

Godet, Yann ;

Angelot-Delettre, Fanny ;

Barisien, Christophe ;

Besiers, Christophe ;

Adotevi, Olivier ;

Pouthier, Fabienne ;

Garnache-Ottou, Francine ;

Bole-Richard, Elodie .

CANCERS, 2022, 14 (13)

[6] Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications [J].

Cerneckis, Jonas ;

Cai, Hongxia ;

Shi, Yanhong .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)

[7] Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies [J].

Cichocki, Frank ;

van der Stegen, Sjoukje J. C. ;

Miller, Jeffrey S. .

BLOOD, 2023, 141 (08) :846-855

[8] IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities [J].

Du, Li ;

Nai, Yaru ;

Shen, Meiying ;

Li, Tingting ;

Huang, Jingjing ;

Han, Xiaojian ;

Wang, Wang ;

Pang, Da ;

Jin, Aishun .

FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8

[9] Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications [J].

Farina Silveira, Caio Raony ;

Corveloni, Amanda Cristina ;

Caruso, Samia Rigotto ;

Macedo, Nathalia Araujo ;

Brussolo, Natalia Moscheta ;

Haddad, Felipe ;

Fernandes, Taisa Risque ;

de Andrade, Pamela Viani ;

Orellana, Maristela Delgado ;

Guerino-Cunha, Renato Luiz .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[10] CAR-T overdrive: harnessing inosine for metabolic rewiring and stemness induction [J].

Farrera-Sal, Marti ;

Schmueck-Henneresse, Michael .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)

← 1 2 3 4 5 6 7 →